Kerala HC directs Health Ministry, DoP to reply on unaffordability of patented cancer drug Ribociclib Roshni Dhar4 Oct 2022 11:19 AM GMTThe Kerala High Court has directed the Department of Pharmaceuticals (DoP) and a competent officer of Union Health Ministry to file their reply on the...
Health Bulletin 3/October/2022 Roshni Dhar3 Oct 2022 11:54 AM GMTHere are the top health news for the day:NMC seeks report on suicides by medicos, directs institutes to submit data Taking cognizance of the...
Kerala HC directs Health Ministry, DoP to reply on unaffordability of patented cancer drug Ribociclib Farhat Nasim2 Oct 2022 10:30 AM GMTThiruvananthapuram: The Kerala High Court has directed the Department of Pharmaceuticals (DoP) and a competent officer of Union Health Ministry to...
Novartis Kisqali adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer Ruchika Sharma11 Sep 2022 9:48 AM GMTBasel: Pharma major, Novartis, has announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program,...
Ribociclib with letrozole prolongs overall survival in advanced breast cancer: NEJM Medha Baranwal22 March 2022 3:30 AM GMTUSA: Recent data from MONALEESA-2 revealed that first-line therapy with a combination of ribociclib plus letrozole showed a significant overall...
